Tianjin Pharmaceutical Da Ren Tang Group Future Growth
Future criteria checks 3/6
Tianjin Pharmaceutical Da Ren Tang Group is forecast to grow earnings and revenue by 20.8% and 10% per annum respectively. EPS is expected to grow by 21% per annum. Return on equity is forecast to be 21.7% in 3 years.
Key information
20.8%
Earnings growth rate
21.0%
EPS growth rate
Pharmaceuticals earnings growth | 19.5% |
Revenue growth rate | 10.0% |
Future return on equity | 21.7% |
Analyst coverage | Low |
Last updated | 16 Aug 2024 |
Recent future growth updates
Recent updates
Some Shareholders Feeling Restless Over Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) P/E Ratio
Jul 26Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet
Jul 05Fewer Investors Than Expected Jumping On Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329)
Apr 18Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Has A Rock Solid Balance Sheet
Mar 18Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 10,493 | 1,610 | N/A | 1,228 | 3 |
12/31/2025 | 9,593 | 1,362 | N/A | 991 | 3 |
12/31/2024 | 8,790 | 1,150 | N/A | 1,219 | 3 |
6/30/2024 | 8,099 | 922 | 1,008 | 1,121 | N/A |
3/31/2024 | 8,050 | 915 | 664 | 779 | N/A |
12/31/2023 | 8,222 | 987 | 548 | 688 | N/A |
9/30/2023 | 8,479 | 991 | 511 | 632 | N/A |
6/30/2023 | 8,563 | 1,116 | 591 | 711 | N/A |
3/31/2023 | 8,514 | 1,063 | 679 | 785 | N/A |
12/31/2022 | 8,249 | 862 | 569 | 677 | N/A |
9/30/2022 | 7,118 | 837 | 188 | 302 | N/A |
6/30/2022 | 7,042 | 775 | 433 | 572 | N/A |
3/31/2022 | 6,970 | 756 | 656 | 818 | N/A |
12/31/2021 | 6,908 | 769 | 695 | 852 | N/A |
9/30/2021 | 6,999 | 846 | 770 | 937 | N/A |
6/30/2021 | 6,954 | 801 | 570 | 737 | N/A |
3/31/2021 | 6,775 | 705 | 472 | 646 | N/A |
12/31/2020 | 6,604 | 662 | 482 | 671 | N/A |
9/30/2020 | 6,773 | 657 | 425 | 633 | N/A |
6/30/2020 | 6,751 | 602 | 414 | 643 | N/A |
3/31/2020 | 6,896 | 605 | 291 | 519 | N/A |
12/31/2019 | 6,994 | 626 | 290 | 495 | N/A |
9/30/2019 | 6,847 | 606 | 125 | 297 | N/A |
6/30/2019 | 6,780 | 595 | 111 | 294 | N/A |
3/31/2019 | 6,497 | 578 | 109 | 287 | N/A |
12/31/2018 | 6,359 | 562 | 174 | 350 | N/A |
9/30/2018 | 6,084 | 517 | 154 | 332 | N/A |
6/30/2018 | 5,814 | 512 | 35 | 167 | N/A |
3/31/2018 | 5,823 | 516 | N/A | 170 | N/A |
12/31/2017 | 5,689 | 476 | N/A | -4 | N/A |
9/30/2017 | 5,747 | 433 | N/A | 219 | N/A |
6/30/2017 | 5,952 | 443 | N/A | 315 | N/A |
3/31/2017 | 6,081 | 438 | N/A | 304 | N/A |
12/31/2016 | 6,243 | 424 | N/A | 418 | N/A |
9/30/2016 | 6,845 | 467 | N/A | 378 | N/A |
6/30/2016 | 6,997 | 471 | N/A | 280 | N/A |
3/31/2016 | 7,104 | 452 | N/A | 326 | N/A |
12/31/2015 | 7,081 | 451 | N/A | 361 | N/A |
9/30/2015 | 7,026 | 436 | N/A | 208 | N/A |
6/30/2015 | 7,114 | 398 | N/A | 338 | N/A |
3/31/2015 | 7,156 | 375 | N/A | 424 | N/A |
12/31/2014 | 7,087 | 358 | N/A | 287 | N/A |
9/30/2014 | 6,621 | 372 | N/A | 408 | N/A |
6/30/2014 | 6,267 | 361 | N/A | 261 | N/A |
3/31/2014 | 6,113 | 336 | N/A | 158 | N/A |
12/31/2013 | 6,010 | 352 | N/A | 213 | N/A |
9/30/2013 | 5,749 | 307 | N/A | -14 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 600329's forecast earnings growth (20.8% per year) is above the savings rate (2.9%).
Earnings vs Market: 600329's earnings (20.8% per year) are forecast to grow slower than the CN market (23.1% per year).
High Growth Earnings: 600329's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 600329's revenue (10% per year) is forecast to grow slower than the CN market (13.3% per year).
High Growth Revenue: 600329's revenue (10% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 600329's Return on Equity is forecast to be high in 3 years time (21.7%)